STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Non-peptide

Cardarine

Also known as

GW501516 · GW-501516 · GW 501516 · GW1516 · GW-1516 · GW 1516 · GW-501,516 · GSK-516 · Endurobol · Cardarine (Endurobol)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Non-peptide Some talk Systemic Oral Metabolic research compounds

Systemic — oral GW501516 is a PPARδ agonist, not a SARM; endurance and lipid discussion carries an unresolved rodent tumor warning.

What people say Cardarine (GW501516) is an oral small-molecule PPARδ agonist, not a SARM. It reached short human metabolic and lipid studies but is not approved for human use, and rodent carcinogenicity is a central safety concern. Doses people talk about
Healthy-men lipid study2.5 or 10 mg oral once daily for 2 weeks

Placebo-controlled study in 24 healthy men.

Low-HDL phase 2 study2.5, 5, or 10 mg oral once daily for 12 weeks

Placebo-controlled study in 268 participants; lipid endpoints do not establish long-term safety.

Community performance band~10–20 mg/day

Repeated in bodybuilding and endurance discussions; gray-market identity and reporting are unverified.

Anti-doping reports~10–20 mg/day for ~6–8 weeks

Abuse-pattern summaries, not an approved medical regimen or risk-safe cycle.

Minority sublingual reports~3 mg claimed; frequency unspecified

Occasional forum claim, not a trial arm; route, identity, absorption and oral equivalence are unverified.

These rows report study arms and community patterns; they are not a safe-dose claim, progression, or risk threshold.

Half-life & effect duration

Half-life in the body
  • Community / secondary estimateAbout 12–24 hours
Felt duration people report
  • Endurance reportsChanges within a week in some accounts; no effect after about 2 weeks in another
  • Other experiencesAnxiety by days 7–9, or lower energy for weeks after stopping
Timing context & sources
How it may feel Accounts range from no noticeable effect after roughly two weeks to improved endurance within about a week. Anxiety, overactivation or lower energy after stopping also appear. Training, other drugs and uncertain product identity limit attribution.
Cycles people discuss Human studies used daily oral exposure for two or twelve weeks. Forum six-to-eight-week ‘cycles’ are anti-doping and bodybuilding patterns, not evidence that risk clears when a cycle ends. Timing Morning or pre-cardio placement appears in reports, including 20–30- and 30–45-minute lead times; these are habits, not measured onset. Food choices and occasional AM/PM splits likewise do not establish superior exposure. Stacks Forums combine cardarine with SARMs, stimulants, or supplements. Co-use and unverified gray-market products make both benefit and adverse-effect attribution weak. Access talk SARM-shop shelf, PPAR molecule: Sold as 5–10 mg RUO caps next to ostarine. That shelf is why people think it is a SARM. It is not. Labs people mention Lipid panel is the actual human signal: Trial-like HDL up / TG and LDL down at ~2.5–10 mg is what risk-aware logs pull pre/mid/post. Watch for Carcinogenicity (rodent, primary risk story): GSK-era 104-week daily oral carcinogenicity studies in rats (Geiger et al., 2009 SOT abstract) and mice (Newsholme et al., 2009 SOT abstract) reported widespread neoplasms / multi-organ tumors. Peer-reviewed full papers were not the main public source — abstracts + secondary citations drive the record. Development was stopped.
Related
SR9009SLU-PP-332SLU-PP-915GW0742AICAR

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

The checked public primary human reports did not establish an elimination half-life.

They document once-daily oral study designs at 2.5–10 mg over two or twelve weeks, which is not itself a half-life measurement.

Absence from the checked reports is not proof that no PK study exists; secondary 12–24-hour claims were not promoted to a measured value.

Felt duration people report

The inspected accounts do not establish a dependable single-dose felt duration.

Some reported endurance changes within a week, one reported anxiety by days seven to nine, another reported no effect after about two weeks, and one described lower energy for weeks after stopping a six-week course.

Training adaptation, expectancy, product identity, dose, co-use and selection bias prevent causal timing or prevalence estimates.

  • Cardarine journey (opens in a new tab)ExternalJob reported no clear benefit on days 1 and 6 or at about two weeks and described unchanged resting heart rate; a different positive reply included phenibut co-use.Anonymous, unverified products and uncontrolled training; one positive report includes another drug, and the original poster did not report a racing-heart measurement.
  • GW501516/Cardarine — amazing cardio benefits but unexpected anxiety (opens in a new tab)A 43-year-old CrossFit participant reported a training increase, endurance by about day seven and nervousness or anxiety by day nine, then stopping on day ten.Single anonymous report with unverified product and training confounding; no racing-heart measurement was reported, and the restart plan was not a completed follow-up.
  • 6-week cycle of cardarine GW501516 (opens in a new tab)The poster claimed 20 mg/day for six weeks, stated that nothing else was used, described easier running/endurance, then lower energy, motivation and sharpness after stopping.Single anonymous self-report, unverified product and dose, no control group; a co-use denial is not verification and post-stop symptoms cannot establish withdrawal or causality.

Other context in this card

  • USADA — What Should Tested Athletes Know About GW1516? (opens in a new tab)Identity and legal-status sections: GW1516/cardarine is a PPARδ agonist often mis-marketed as a SARM, prohibited in sport, and not available as an approved medication.Anti-doping education source, not a primary pharmacokinetic study; safety summary should be read alongside primary human and animal records.

What people say 17

  • Endurance (community): Most repeated payoff — longer steady-state cardio, less perceived effort at familiar paces, delayed “bonk,” more weekly cardio volume before fatigue caps sessions. Not a caffeine-style kick. forumanecdote
  • Fat-loss / recomp talk: Forums treat it as a cut/recomp assist when diet and steps are already dialed — rarely as a solo “melt fat without deficit” drug. Attribution is heavily confounded by stacks, stims, and cardio volume. forum
  • Non-androgenic profile: No classic AAS sides (acne, hairline, voice, HPTA shutdown from androgen receptor agonism). Core appeal for users who want cardio/metabolic help without a full steroid stack. forum
  • Tren / harsh-androgen cardio offset: Recurring PED lore — cardarine co-run to blunt trenbolone’s notorious cardio-crush so prep cardio stays doable. Uncontrolled, confounded, and risk-additive. forumanecdote
  • Volume tolerance: Logs claim more frequent LISS/HIIT before fatigue limits; hard to separate from training adaptation. anecdote
  • Evidence honesty on benefits: Strongest controlled human signals are short-window lipids / hepatic fat / fat-ox markers at 2.5–10 mg. “Race-day endurance miracle” and large fat-loss claims are mostly animal + anecdote. trialforum
  • 2025–26 “lipid support on a SARM cycle”: r/SARMs still asks whether low-dose GW can offset LGD/ostarine HDL crash. Trial GW raised HDL in clean settings; it does not cancel stacked oral-SARM lipid damage or the tumor file. forumtrial
  • “Third lung” logs: 2026 cut diaries still lead with easier incline walks and race-block cardio, then the cancer googling. Confounded by the rest of the stack. forumanecdote
  • Mouse / rodent endurance: High-profile Evans-lab and follow-on work: PPARδ activation and GW501516 regimens dramatically improved running performance; Kunming-mouse metabolomic work reported large running-distance gains and higher SDH-positive oxidative fiber share in both trained and untrained animals (community summaries often say “nearly doubled” distance — check primary figure for exact group means). animal
  • Fuel shift / fat oxidation (human short trials): Daily 2.5 mg and 10 mg for ~2 weeks improved skeletal-muscle fat utilization markers and post–high-fat-meal triglyceride handling vs placebo in healthy men. trial
  • Lipids — Phase 1 healthy men (2 weeks): Placebo vs 2.5 mg vs 10 mg/day in 24 men — significant HDL increase and triglyceride reduction; described as well tolerated over that window with no meaningful liver-enzyme or muscle-protein AE signal in the published report. trial
  • Lipids / hepatic fat — small overweight cohort: ~10 mg/day × 2 weeks in six moderately overweight subjects — fasting TG, apoB, LDL-C, and insulin down; ~20% reduction in liver fat content and ~30% drop in urinary isoprostanes reported; skeletal-muscle CPT1b expression up. trial
  • Lipids — larger Phase 2 dyslipidemia trial: Once-daily GW501516 2.5 / 5 / 10 mg or placebo for 12 weeks (n≈268, low HDL entry) — HDL-C increases up to ~16.9% at 10 mg and apoA-I increases up to ~6.6%; LDL and other atherogenic markers also moved favorably in published ATVB write-up. trial
  • Lipoprotein kinetics (dyslipidemic men): ~2.5 mg/day in centrally obese dyslipidemic men — VLDL catabolism up, apoA-I/A-II production shifts, apoC-III and LDL-apoB production down; CETP activity decreased; insulin resistance not clearly fixed in that design. trial
  • Primate lipids: Obese rhesus monkeys — HDL up, VLDL/LDL-type lipid improvements, lower serum insulin signals in classic preclinical work. animal
  • Not a mass builder: Even sympathetic write-ups note little hypertrophy signal; anti-catabolic framing is soft and secondary to endurance/lipids. forumtrial
  • Lipids (human programs): Phase 2-era discussions often cite HDL-raising effects around the 10 mg oral band in lipids trials — separate from cancer risk debates. trial

Doses people talk about 20

  • Community “standard”: ~10 mg oral once daily is the most repeated bodybuilding/endurance forum default. forum
  • Community common performance band: ~10–20 mg/day total — widely echoed in logs, vendor charts, and anti-doping abuse summaries. forumtrial
  • Lower / risk-aware / smaller-user band: ~5–10 mg/day; some women’s-focused secondary write-ups cluster 5–10 mg. Still research-chem territory, not a validated sex-specific regimen. forum
  • Upper community talk: 15–20 mg/day advanced/contest logs; occasional higher experimental totals appear but are not the modal advice and sit closer to HED-margin debates from rodent tumor doses. forumanecdote
  • Once daily vs split: Trials used once-daily oral. Forums usually keep 10 mg QD; at ~15–20 mg some split AM/PM for habit or GI tolerance, not because of a published short half-life requiring multi-dosing like SR9009. trialforum
  • Pre-cardio timing lore: Minority dose ~20–30 minutes before long sessions or place the daily dose on training mornings; others just pick a fixed clock time. Uncontrolled. anecdoteforum
  • With vs without food: Community generally “either works”; no strong clinical food-effect package is what guides forums. Consistency > meal hacking in most logs. forum
  • Capsules / tablets: Fixed 5 mg or 10 mg caps common on gray market; underfill and mislabel still apply. forum
  • Potency / identity caveat: Without third-party testing, “I took 20 mg and felt nothing” can mean fake product, degraded liquid, or wrong molecule as easily as true non-response. forum
  • Not injectable culture: Unlike SLU-PP-332 debates, modern cardarine talk is overwhelmingly oral; injectable GW is not a standard community route. forum
  • Pre-cardio 30–45 min: 2026 protocol blogs still place the daily swallow before the session “so the volume is actually done.” Uncontrolled timing lore. forum
  • Sublingual micro (minority): Occasional 2026 posts claim ~3 mg sublingual “helps enough” as a cancer-anxiety compromise. Not a trial arm. anecdote
  • Rec chart: Often ~10–20 mg oral daily in performance forums — still research chem, not approved. forum
  • Framing: All human figures below are historical trial exposures or community/anti-doping discussion ranges — not medical advice, not consumption guidance, not a protocol. forumtrial
  • Trial — healthy men lipids (2 weeks): Placebo vs 2.5 mg vs 10 mg per day (n=24). trial
  • Trial — overweight hepatic-fat / metabolic markers (2 weeks): ~10 mg/day (n=6 in the widely cited short study). trial
  • Trial — dyslipidemic men kinetics: ~2.5 mg/day oral. trial
  • Anti-doping literature dose pattern: Forensic/hair and doping papers summarize abuse at roughly 10–20 mg/day oral for ~6–8 weeks. trial
  • Trial band (human): ~2.5–10 mg oral once daily appears across published Phase 1/2 metabolic and dyslipidemia work. trial
  • Trial — larger low-HDL Phase 2 (12 weeks): 2.5 mg, 5.0 mg, or 10.0 mg once daily vs placebo (n≈268). HDL rise largest at 10 mg in the published report. trial

How it may feel 10

  • Day 1 / first doses: Usually no stimulant buzz, no pump drug feel. Early notes (if any) are subtle breathing ease on easy cardio — many feel nothing the first few days. Other inspected accounts include no change at about two weeks, anxiety/overactivation by days 7–9, and lower energy after stopping a six-week course; these do not establish one felt window. forumanecdote
  • Days 1–7: Subtle cardio economy or “same pace, less winded” is the early story when people notice anything; GI or mild headache can also appear early in minority logs. forumanecdote
  • Weeks 1–2: Common first honest checkpoint for endurance assist — longer sessions or less RPE at familiar heart rates. Matches trial windows where lipid/fat-ox markers already moved. forumtrial
  • Weeks 3–4: Frequent keep/stop decision point for risk-aware users (cancer discourse) vs “this is working for my cut cardio.” Non-responders start blaming product quality or underdose. forum
  • Weeks 6–8: Modal full community “cycle” end for bodybuilding/endurance blocks; contest-prep users often pin cardio quality gains here while still deep in deficit. forum
  • Weeks 8–12: Some extend toward the upper end of published Phase 2 exposure length; others refuse to stay that long given rodent tumor data. No consensus “safe” long block. forumtrial
  • Post-cycle (days–weeks after stop): Subjective endurance often fades toward baseline while residual fitness from the extra training may stick. Not described as a classic rebound crash compound. anecdote
  • No change by ~3–4 weeks: Threads usually re-check diet, sleep, base cardio, dose math, and gray-market purity/label strength before assuming the mechanism “doesn’t work.” Dose-escalation without product verification is common bad practice in the same threads. forum
  • Weeks 4–6 “stopped working” lore: Some 2026 research writeups blame carnitine depletion rather than true tolerance and add L-carnitine next to GW. Uncontrolled. forum
  • Clean feel: Non-androgenic “no acne, no shutdown, no buzz” is still why people run it on cuts — and why SARM shops keep mislabeling it. forum

Around the dose 6

  • Clock: Forums describe morning use or placement roughly 30–45 minutes before cardio; this is reported timing, not measured onset or superiority. Historical trials used once-daily oral dosing. forumtrial
  • Training: Zone-2 and incline walks appear in existing “cardio in a bottle” discussion; some notes contrast those sessions with no change during sedentary cuts. Reports cannot separate compound effects from training, expectancy or product identity. forum
  • Food: Forum posts vary on taking it with or without food; the checked sources do not establish a clinically validated food-effect rule. forum
  • Activity and stacks: Existing notes describe extra steps on dose days and L-carnitine alongside “weeks 4–6 fade” lore. These are community practices, not established timing rules or proof of depletion. forum
  • Lipid versus endurance contexts: Existing notes mention 10 mg oral use for both HDL/TG bloodwork interest during SARM cuts and treadmill performance. These are different, often confounded goals; neither establishes a safe amount or cancels the tumor concern. forumtrial
  • Avoid: Treating a SARM-shop bottle as proof it is a SARM, and treating short cycles as a cleared cancer file. forum

Cycles people discuss 9

  • Modal community length: ~6–8 week oral blocks dominate bodybuilding and endurance-forum cycle charts. Matches anti-doping abuse-pattern summaries. forumtrial
  • Shorter probes: ~4 weeks for “does cardio feel easier / do lipids move on labs” or cut-phase assist without a long continuous exposure. forum
  • Longer runs: Some extend to ~8–12 weeks (aligned with the 12-week Phase 2 exposure ceiling in published lipid work); many risk-aware users refuse multi-month continuous use because carcinogenicity data were chronic-duration rodent studies. forumtrial
  • Hard upper folklore: Recurring “no more than ~8–12 weeks” or “cap around 3 months then take time off” style rules (including older Guerrilla Chemist–style forum paraphrases) — community risk management, not a proven safety threshold. forum
  • Time off: Off ≈ on length is the common heuristic (e.g. 8 weeks on / 8 weeks off); practices vary widely and have no clinical washout science for tumor risk. forum
  • No solo PCT: Cardarine alone is not treated as HPTA-suppressive; classic SERM/AI PCT is discussed only when stacked with suppressive SARMs/AAS. forumtrial
  • Re-runs: Seasonal race blocks, contest prep, or cut seasons are commonly described; serial multi-year human safety is unstudied. forum
  • Bloodwork culture: Risk-aware logs sometimes pull lipids + liver enzymes pre/mid/post — lipids are the marker most likely to move in trial-like directions; enzymes are monitored more from stack confounders than a universal cardarine hepatotoxicity signal. forum
  • Continuous low-dose “cruise” talk: Exists at the edges; most cancer-discourse threads push against open-ended daily use given absence of long-term human data and all-doses-positive rodent tumor abstracts. forum

Timing 10

  • Forum / secondary assumption: ~12–24 hours (many write-ups round to ~24 h from QD trial design). Treat as inference, not a package-insert PK table. forum
  • Practical timing: Fixed daily clock time is the norm; morning dosing is popular so daytime cardio sits under coverage. forum
  • Not a multi-dose-per-day drug like SR9009: SR9009 community PK lore is short (split 3–4×/day); cardarine culture is QD (optional split only at higher totals). forum
  • Feel type vs kinetics: Pathway/transcriptional metabolic story — not a 90-minute stimulant. Same-day “I feel it” is unreliable; multi-week cardio economy is the claimed arc. forum
  • Washout for tested athletes: “I’m clear after X days” forum math is reckless — matrix (urine vs hair), dose history, and lab methods differ; banned means do not use if subject to testing. trialforum
  • Downstream biology: PPARδ-driven gene programs can outlast peak plasma in principle (biology inference); users still report subjective endurance fading after stopping. trialanecdote
  • Clinical half-life gap: Formal human t½ was not cleanly published in the widely circulated trial summaries; all human trials used once-daily oral dosing. trial
  • Urine detection (anti-doping): Sulfone metabolites of GW1516 monitored by LC-MS/MS; published work reports detectability in urine up to ~40 days after a single oral 15 mg dose (GW0742 shorter in the same paper, ~20 days). trial
  • Hair detection: GW501516 has been quantified in human hair segments of an abuser (e.g. tens of pg/mg in 2 cm segments in published forensic case work) — extends detection narrative beyond urine washout talk. trial
  • WADA status: Prohibited at all times (hormone and metabolic modulator class; historically also framed under gene-doping concerns). Positive tests and sanctions documented across cycling, athletics, combat sports, etc. trial

More on what it is 11

  • Street / fitness names: Cardarine and Endurobol dominate gray-market and forum talk; research codes GW501516, GW1516, GSK-516. forum
  • Not a SARM: Does not bind the androgen receptor. Fitness shops and “SARM stacks” frequently mislabel it; mechanism is nuclear-receptor metabolic modulation, not selective anabolism. trialforum
  • Why people care: Animal endurance and oxidative-metabolism data + early human lipid/fat-oxidation signals → “endurance / fat-ox research chem” culture. Marketed narrative is easier steady cardio and recomp assist, not a stimulant buzz. animalforum
  • Evidence honesty: Short human lipid/metabolic exposures exist at low-mg daily doses; athletic “performance” claims rest mainly on animal endurance models + uncontrolled community logs — not modern sports RCTs. trialforum
  • 2026 still not a SARM: Shops and r/SARMs still shelve it with ostarine. Mechanism is PPARδ, WADA files it at S4.4.1 metabolic modulators, not S1.2 anabolic agents. Enriching this card is not adding a new SARM. trialforum
  • Cancer-math fight got louder: 2026 MPMD/Reddit posts argue naive “rats got hundreds of mg” copes fail allometric HED — lowest tumor arms map nearer common 10–20 mg logs, and tumors were reported at every tested dose. forumanimal
  • Bro framing: Endurance / zone-2 “cardio in a bottle” lore (GW501516) — also the poster child for cancer-scare debates. forum
  • What it is: Synthetic selective peroxisome proliferator-activated receptor delta (PPARδ / PPARβ/δ) agonist (C21H18F3NO3S2, ~453.5 g/mol). Invented in a Ligand Pharmaceuticals / GlaxoSmithKline collaboration (1990s; discovery published ~2001 PNAS). Never approved as a medicine. trial
  • Mechanism (plain): High-affinity PPARδ agonism (literature often cites Ki / EC50 ~1 nM with >~1000-fold selectivity over PPARα and PPARγ) recruits coactivators (e.g. PGC-1α adjacency in rat work) and upregulates fatty-acid oxidation / energy-expenditure gene programs in muscle; fuel-preference story shifts toward lipid use. trialanimal
  • Development stop: Completed Phase I/II-era metabolic/dyslipidemia work, then abandoned ~2007 after chronic rodent carcinogenicity showed multi-organ tumors. WADA later banned it and issued a rare explicit health warning to athletes. trialanimal
  • Legal / status snapshot: Unapproved; WADA prohibited at all times (S4 metabolic modulators lineage; added ~2009, recategorized from gene-doping framing). AU has treated it as a high-control / poisonous-substance class item in public advisories. Sold only as “research chemical” online — not a legal dietary supplement. trial

Stacks 12

  • Cardarine + Ostarine (MK-2866): Classic cut-phase pair — GW for cardio/fat-ox narrative, Ostarine for soft muscle retention in deficit. Community Ostarine often ~10–25 mg/day alongside GW ~10–20 mg/day for ~6–8 weeks (ranges vary; stack suppression risk is from the SARM, not GW). forum
  • Cardarine + SR9009 (Stenabolic): Named “endurance / metabolic duo.” GW usually once daily; SR9009 community charts demand multi-dose splits (e.g. totals ~20–30 mg/day split many times) because of short-half-life lore and poor oral-F debates. Confounded dual attribution is the norm. forum
  • Cardarine + Andarine (S4) ± Ostarine: Older cutting-stack templates (example forum layouts: S4 split high-mg totals + GW ~20 mg + optional SR9009). Vision sides from S4 dominate risk talk in those threads. forum
  • Cardarine + LGD-4033 / other stronger SARMs: Less “beginner,” more recomp/cut with heavier suppression and lipid confounders; still seen in vendor “shred stack” marketing. forum
  • Cardarine + MK-677: Sometimes paired so MK covers hunger/sleep/IGF narrative while GW covers cardio — appetite and water from MK can fight the cut. forum
  • Cardarine + caffeine / yohimbine / clen-type stims: Fat-loss and HR confounds; stim sides can be blamed on or masked by the stack. forum
  • Cardarine during trenbolone or other harsh AAS: PED-specific “keep my cardio” support role — does not cancel tren risks; adds unquantified long-term liability. forum
  • Contest prep / race block context: Rarely solo — layered on aggressive diet, high steps, and other PEDs; fat-loss credit is shared. forum
  • Vs SLU-PP-332 / exercise-mimetic class: Comparison shopping as next-gen “cardio mimetic”; different receptor class (ERR vs PPARδ) and different oral-vs-inject culture. No head-to-head human trial. forum
  • Stack PCT note: PCT discussions track the suppressive agents in the stack; cardarine alone does not create a standard PCT requirement in forum doctrine. forum
  • 2026 SARM-cycle lipid add-on: Low-dose GW next to LGD/ostarine for HDL talk — still risk-additive, still not a SARM itself. forum
  • vs SLU-PP-332 / 915: Comparison shopping as the “next cardio mimetic” with a different (ERR) receptor and a different oral-F fight. No head-to-head human trial. forum

Access talk 5

  • SARM-shop shelf, PPAR molecule: Sold as 5–10 mg RUO caps next to ostarine. That shelf is why people think it is a SARM. It is not. forum
  • Research chem only: No legitimate endurance or HDL prescription path. “Dietary supplement” listings are the enforcement story, not QC. trialforum
  • Identity / fill: Underfilled liquids and wrong-molecule bottles still explain “I felt nothing at 20 mg.” forum
  • Do not add new SARMs to chase this job: This card is the PPAR already on the map. GW0742 is the same-door research analog, not a SARM either. forum
  • Not a pharmacy lipid drug: Unapproved. WADA prohibited at all times (S4.4.1 metabolic modulators). Australia public advisories have treated GW1516 as a high-control / poisonous-substance class item. trial

Labs people mention 4

  • Lipid panel is the actual human signal: Trial-like HDL up / TG and LDL down at ~2.5–10 mg is what risk-aware logs pull pre/mid/post. trialforum
  • AST/ALT: Watched more because of stacked orals/SARMs than a unique GW hepatotoxin fingerprint. forum
  • Not a cancer screen: There is no community lab that clears the rodent tumor file. Scanning lymph nodes after a cut is anxiety, not surveillance. forum
  • HDL on a SARM stack: If HDL is already crashed from LGD/RAD, do not read a GW add-on as “lipids fixed.” forum

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 20

  • Human-equivalent dose debate (community): Optimistic forum math once claimed “rodents got the equivalent of hundreds of mg in humans” using naive mg/kg scaling of high arms. More careful allometric write-ups put human-equivalent of the lowest tumorigenic ~3 mg/kg rodent arm roughly in the ~30–45 mg/day ballpark for a ~70–80 kg adult — only a few-fold above common 10–20 mg recreational totals. Margin is contested; it is not “infinite headroom.” forumanimal
  • Liver / GI (community): Minority reports of enzyme bumps, nausea, stomach discomfort, or loose stool; stacks, alcohol, oral SARMs, and diet often confound. Not a universal hepatotoxin signal like some orals, but labs appear in cautious protocols. forum
  • Headache / nonspecific: Occasional headache, fatigue, mild dizziness, muscle aches — no single dominant AE fingerprint across logs. forumanecdote
  • Blood pressure / HR talk: Occasional low-BP or odd cardio-feel anecdotes; less defined than stimulant stacks. anecdote
  • Not HPTA-suppressive alone: Does not replace need for PCT when stacked with suppressive agents; also does not protect lipids from SARM/AAS damage just because trial GW raised HDL in clean settings. forumtrial
  • 2026 hypochondria posts: r/ResearchCompounds-style logs after a summer 10–20 mg cut describe checking lymph nodes and googling lymphoma from a new freckle — the endurance was “third lung,” the hangover is the rat abstracts. forumanecdote
  • HED is not a green light: 2026 writeups putting the lowest rodent tumor dose near ~10–40 mg human-equivalent are the counter to “I only run 10 mg so I’m fine.” There is still no human carcinogenicity epidemiology. forumanimal
  • Carcinogenicity (rodent, primary risk story): GSK-era 104-week daily oral carcinogenicity studies in rats (Geiger et al., 2009 SOT abstract) and mice (Newsholme et al., 2009 SOT abstract) reported widespread neoplasms / multi-organ tumors. Peer-reviewed full papers were not the main public source — abstracts + secondary citations drive the record. Development was stopped. animaltrial
  • All doses / no clean NOAEL for tumors: Summaries of those bioassays state tumors appeared at every tested dose level, including the lowest (~3 mg/kg/day class figures widely repeated for both species). Absence of a clear no-tumor dose is why regulators and WADA treat the signal as disqualifying for chronic human use. animal
  • Duration mismatch: Rodent cancer bioassays were essentially lifelong continuous dosing (~2 years). Human trials were weeks (often 2; Phase 2 up to 12). Short clean human windows do not clear multi-year or repeated-cycle risk. trialanimal
  • Mechanism concern: PPARδ activation itself is implicated in pro- and anti-tumor literature depending on model; a 2018 colitis-associated colorectal cancer mouse paper reported GW501516 enhanced tumor growth via inflammation / GLUT1 / SLC1A5 pathways. Signal is not a single tidy story. animal
  • WADA health alert: In 2013 WADA took the rare step of warning athletes that clinical approval has not and will not be given, citing serious health risk — not only a “you will test positive” notice. trial
  • Human short-term trial AE picture: Published low-mg, multi-week metabolic studies generally reported good short-term tolerability without a dramatic AE cluster — but samples were small, durations short, and endpoints were not long-term oncology surveillance. trial
  • Not FDA/EMA approved: No legal therapeutic product for endurance, fat loss, or lipids. Marketing as a dietary supplement is not a legitimate pathway in major jurisdictions (USADA notes reporting of such sites to FDA). trial
  • Jurisdiction extremes: Australia public materials have classified GW1516 as a high-control / poisonous substance class item in advisories — legal risk beyond sport bans. trial
  • Risk-framing honesty: Community split between “short cycles at 10 mg are fine, rats got mega-doses for life” vs “no NOAEL + thin human long-term data = unacceptable.” Neither camp has human carcinogenicity epidemiology. Sparse-honesty requires stating that gap. forumtrial
  • Cancer caution (preclinical): Long-term rodent programs reported tumors across tested dose bands — a core reason many treat Cardarine as high-risk research chem despite lipid/endurance lore. animal
  • Why serious people flinch: Rodent tumor findings at research doses keep coming up whenever someone posts a “just run 10 mg” stack. animal
  • WADA / tested sport: Still prohibited at all times. Hair and ~40-day urine metabolite stories did not get friendlier. trial
  • Pregnancy / unknown populations: No safe-use dataset; irrelevant for research-only framing but forums sometimes ignore this. trial

Updated: 2026-09-01

Evidence mix Mixed trial + community tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →